Revolutionizing KRAS p.G12C therapy in metastatic colorectal cancer: The triumph of dual inhibition.
| Autor: | Ottaiano A; Department of Abdominal Oncology, Istituto Nazionale Tumori di Napoli, IRCCS 'G. Pascale', via Mariano Semmola, 80131 Naples, Italy. Electronic address: a.ottaiano@istitutotumori.na.it., Santorsola M; Department of Abdominal Oncology, Istituto Nazionale Tumori di Napoli, IRCCS 'G. Pascale', via Mariano Semmola, 80131 Naples, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Med (New York, N.Y.) [Med] 2023 Dec 08; Vol. 4 (12), pp. 857-859. |
| DOI: | 10.1016/j.medj.2023.11.005 |
| Abstrakt: | The management of refractory metastatic colorectal cancer patients with the KRAS p.G12C mutation presents a significant unmet need, with limited success using standard therapies. The study by Fakih et al. highlights the potential of sotorasib and panitumumab combination therapy in this clinical context, paving the way for a promising personalized therapeutic approach. 1 . Competing Interests: Declaration of interests The authors declare no competing interests. (Copyright © 2023 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|